Giuseppe A Palumbo
Overview
Explore the profile of Giuseppe A Palumbo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
1520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duminuco A, Bulla A, Rosso R, Romeo M, Cambria D, La Spina E, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006658
Background: Immune system impairment is frequently reported in patients affected by hemoglobinopathies due to various mechanisms, including iron accumulation, antigenic stimulation due to numerous transfusions, chronic hemolysis, and a general...
2.
Oliva E, Guo S, Lord-Bessen J, Yucel A, Latagliata R, Breccia M, et al.
Front Oncol
. 2025 Feb;
15:1507854.
PMID: 39990686
Background: Myelodysplastic neoplasms (MDS) are characterized by ineffective hematopoiesis, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia. One of the main treatment goals is improving...
3.
Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M, et al.
Ann Hematol
. 2025 Jan;
104(1):241-251.
PMID: 39831987
Calreticulin (CALR) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with...
4.
Spampinato M, Giallongo C, Giallongo S, La Spina E, Duminuco A, Longhitano L, et al.
J Transl Med
. 2025 Jan;
23(1):69.
PMID: 39810250
Background: Clonal myeloproliferation and fibrotic transformation of the bone marrow (BM) are the pathogenetic events most commonly occurring in myelofibrosis (MF). There is great evidence indicating that tumor microenvironment is...
5.
Oliva E, Cuzzola M, Porta M, Candoni A, Salutari P, Palumbo G, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519198
The achievement of complete remission (CR) is crucial for acute myeloid leukemia (AML) patients undertaking curative therapy, but relapse often occurs within months, highlighting the need for strategies to prolong...
6.
Tissino E, Gaglio A, Nicolo A, Pozzo F, Bittolo T, Rossi F, et al.
Leukemia
. 2024 Aug;
38(10):2127-2140.
PMID: 39143370
In chronic lymphocytic leukemia (CLL), survival of neoplastic cells depends on microenvironmental signals at lymphoid sites where the crosstalk between the integrin VLA-4 (CD49d/CD29), expressed in ~40% of CLL, and...
7.
Breccia M, Palandri F, Polverelli N, Caira M, Berluti M, Palumbo G, et al.
Front Oncol
. 2024 Aug;
14:1382872.
PMID: 39114304
Myelofibrosis (MF) is a clonal disorder of hematopoietic stem cells characterized by altered bone marrow function and fibrosis. The aim of this narrative review is to report on the most...
8.
Palandri F, Elli E, Morsia E, Benevolo G, Tiribelli M, Beggiato E, et al.
Cancer
. 2024 Jul;
130(24):4257-4266.
PMID: 39078647
Background: Ruxolitinib (RUX) is a JAK1/2 inhibitor approved for the therapy of myelofibrosis (MF) based on clinical trials including only intermediate2-high risk (INT2/HIGH) patients. However, RUX is commonly used in...
9.
Spampinato M, Zuppelli T, Dulcamare I, Longhitano L, Sambataro D, Santisi A, et al.
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065744
Background: Chronic myeloid leukemia is a hematological malignancy characterized by the abnormal proliferation of leukemic cells. Despite significant progress with tyrosine kinase inhibitors, such as Dasatinib, resistance remains a challenge....
10.
Mangione R, Giallongo C, Duminuco A, La Spina E, Longhitano L, Giallongo S, et al.
Antioxidants (Basel)
. 2024 Apr;
13(4).
PMID: 38671937
To date, little is known concerning the circulating levels of biochemically relevant metabolites (antioxidants, oxidative/nitrosative stress biomarkers, purines, and pyrimidines) in patients with primary myelofibrosis (PMF), a rare form of...